The HIV-TB Pathogenesis and Treatment Research Unit, based at the Centre for the Aids Programme of Research in South Africa (CAPRISA), researches ways to reduce the mortality rate and widespread presence of HIV and Tuberculosis (TB) co-infection.
HIV infection is the leading cause of death in South Africa, which has the third highest HIV-related TB problem in the world, with as many as 60% of HIV patients being co-infected with TB.
Key focus areas
- Improving the survival rate of those infected with both HIV and TB by optimising their treatment;
- Sharing reliable information on the links between HIV and TB;
- Promoting the use of clinical trial evidence in real world settings;
- Informing the country’s HIV-TB epidemic policies and practices; and
- Growing South Africa’s HIV-TB co-infection research community.
Overview of the MRC HIV-TB Pathogenesis and Treatment Research Unit research plan:
|Unit Director: Prof Salim Abdool Karim
CAPRISA, Doris Duke Medical Research Institute (2ndFloor),
719 Umbilo Road, Congella, Durban, 4013
Tel office: +27 31 260 4550
|For more information, visit the Centre for the AIDS Programme of Research in South Africa (CAPRISA) Website|